NOV 06, 2016 03:48 PM PST

Drug for Neglected Disease Activated by Newly Found Enzyme

WRITTEN BY: Carmen Leitch
Neglected diseases are those that affect the world’s poor and are usually common in tropical areas. A new discovery could aid in the treatment of one such disease, Visceral leishmaniasis (VL) which is also known as Kala-azar. Researchers at the University of Dundee in New Zealand, an area of research on neglected diseases, have found a protein that can help improve the efficacy of a drug that was recently identified as a therapeutic for VL.

VL, described in the video above, that affects roughly two to four hundred thousand people globally, according to the Centers for Disease Control. It is a parasitic infection that can range from a silent infection, with no symptoms, to more serious cases of fever, weight loss and liver and spleen problems. It primarily affects people in Brazil, India, Nepal, Bangladesh, Ethiopia, South Sudan and Sudan. The current treatments have considerable limitations such as high cost, toxicity, side effects, prolonged administration and drug resistance; there are no vaccines.
"There has been considerable interest in developing new compounds to target diseases like leishmaniasis, particularly because the existing drugs are very unsatisfactory and increasingly becoming unusable due to resistance in the parasite," said Professor Alan Fairlamb, Wellcome Principal Research Fellow in the School of Life Sciences at Dundee. He is the senior author of the work, reported in PLOS Pathogens.
Fairlamb, in collaboration with Dr. Kevin Read and colleagues have previously shown that one drug used to treat tuberculosis, called delamanid, can potentially also treat VL. Their new work with a team at the Wellcome Trust Sanger Institute in Cambridge, UK, identified a protein that is characterized as a nitroreductase – an enzyme that targets nitrogen compounds, and shows that it can improve the efficacy of delamanid as a VL nitro-drug. An example of a nitroreductase is shown below.

The researchers term the newly found protein nitroreductase NTR2. The researchers show that it can result in hypersensitivity to bicyclic nitro compounds like delamanid. Another type of nitroreductase, NTR1, activates other types of nitrogen compounds, monocyclic nitro-drugs.
"One concern has been that if all nitro-drugs are activated by NTR1, then loss of this protein would lead to widespread drug resistance to both unicyclic drugs (fexinidazole) and bicyclic drugs (delamanid). We have discovered this new protein, NTR2 that specifically activates drugs like delamanid but not fexinidazole," explained Fairlamb
"This knowledge is extremely important in that it allows us to design better drugs activated by NTR2 and to suggest drug combinations that will reduce the risk of emergence of drug resistance through loss of either NTR1 or NTR2 activity. It also provides a potential diagnostic marker for resistance should it arise," said Fairlamb.
One drug identified by the researchers, fexinidazole, is undergoing phase II clinical trials in Africa as part of the Drugs for Neglected Diseases initiative. Delamanid has been considered for immediate trials in VL patients.
"Further work is now needed to find the most appropriate partner drugs to be used to increase efficacy and decrease toxicity in patients, to minimize the risk of drug resistance emerging and in designing second generation drugs.” Fairlamb concluded.

If you would like to know more about neglected disease of the world, watch the following video.

Sources: AAAS/Eurekalert! via Dundee University, PLOS Pathogens
About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
NOV 26, 2018
NOV 26, 2018
Behavior Predicting Neural Code Identified
Perceptual choice behavior, taking action based on the information received from the senses is often described by mathematical models...
DEC 08, 2018
DEC 08, 2018
Adaptations Of The Heart To Chronic Exercise
We have all heard that exercise is good for us, particularly for the heart, but many don’t understand precisely how regular, long-term activity affec...
DEC 24, 2018
Cell & Molecular Biology
DEC 24, 2018
Searching for the Secret of Planarians' Regenerative Abilities
There's nothing particularly striking about planarians on first glance, but they can regrow their whole body from a bit of tail....
JAN 07, 2019
JAN 07, 2019
Anti-Epileptic Stem Cells
Researchers from the Texas A&M College of Medicine, demonstrated that grafting of medial ganglionic eminence (MGE)-derived GABA-ergic progenitor cells into the hippocampus subdued the seizure...
DEC 28, 2018
Genetics & Genomics
DEC 28, 2018
The Epigenetic Profile of Sperm is Altered by Cannabis
There has been considerable debate about the safety of marijuana, which has only increased since the drug has been legalized in some states....
JAN 10, 2019
Health & Medicine
JAN 10, 2019
Skin with hair or without hair
study identified that the endogenous secreted Wnt inhibitor DKK2 suppresses the hair follicle development...
Loading Comments...